<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Lymphoma In Vivo Screen

Champions' premier Lymphoma In Vivo Screen provides a robust bank of pretreated and treatment-naïve PDX models to assess breakthrough therapeutics

Now Enrolling until July 31st, 2025

 

 

7 New Extremely Rare PDX Lymphoma Models Now Available

The Lymphoma In Vivo Screen now includes 7 newly added PDX models, expanding the bank to 26 total models—including some of the most difficult-to-access lymphoma subtypes in preclinical research.

New subtypes include:

  • 4 - DLBCL models from patients who relapsed after R-CHOP or following Richter transformation and showed CAR-T19 refractory disease
  • 2 - PTCL-NOS (T-cell lymphoma) models — a highly aggressive, underrepresented subtype
  • 1 - Burkitt lymphoma model with fast-growing, high-grade features 
All new models feature detailed clinical annotation, including treatment history, phenotype, and cytogenetics, and are available for immediate in vivo screening.

Clinically Relevant Lymphoma Models with Key Mutations & Molecular Characteristics

Evaluate your Lymphoma drug candidates on our advanced in vivo screening platform, which features a comprehensive bank of 26 pretreated and treatment-naïve patient-derived xenograft (PDX) lymphoma models. Our carefully curated collection includes models treated with advanced cancer therapies like CAR-T, DICE, and EPOCH. Significantly, the CTG-3879 model featured in the screen is derived from a patient who experienced disease progression following treatment with a combination of lenalidomide and tafasitamab-cxix, an anti-CD19 antibody therapy. 

 Clinically Relevant Models

Living bank of 26 clinically relevant PDX models with key mutations and molecular characteristics.  

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

Champions' leading Lymphoma In Vivo Screen showcases 26 PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history. 

  • Includes advanced Lymphoma models pretreated with advanced cancer therapies such as CAR-T, DICE, and EPOCH.   
  • Includes models with pretreatment resistance history to targeted treatments and the latest immunotherapies, such as lenalidomide and tafasitamab-cxix antibody therapy targeting CD19.
  • Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and more).
  • Several endpoint data options available including Flow Cytometry and IHC to quantify target expression and critical phenotypical changes (available upon request).
  • Terminal tumor collections for target validation is available upon request (Snap Frozen/FFPE)
  • No minimum to enroll & 50% off a Standard of Care Agent arm (selected by Champions)
Lymphoma In Vivo Screen Models Clinical and Molecular Characteristics:
DLBCL in vivo PDX models clinical and molecular characteristics

These Lymphoma models are derived from distinct tumor types and encompass various tumor statuses (primary vs. metastatic), treatment histories (naive vs. pretreated), and mutation burdens. 

Response to Standards of Care - In Vivo
DLBCL in vivo screen may 2024 standard of care Reponses

Treatment responses of three Lymphoma PDX models, CTG-3064, CTG-3793, and CTG-3803, to standards-of-care.

DLBCL Clustering-1
Lymphoma In Vivo Screen PDX Models Mutation Clustering

Utilizing Lumin, our Clustering Heatmap tool is a web-based application designed to visually interpret and analyze complex data through interactive and shareable hierarchically clustered heatmaps. 

  • Visualize expression signatures and the prevalence of driver mutations in each PDX model.
  • Gain profound insights by exploring RNA-seq, WES, proteomics, and phospho-proteomics datasets.
  • Harness quality data from extensive datasets to drive informed decision-making.